HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acne Relief In Brief

This article was originally published in The Rose Sheet

Executive Summary

Isolaz photopneumatic therapy: The "only painless laser treatment for acne" and the only system cleared by FDA to treat comedonal and postular acne, as well as mild to moderate acne (including acne vulgaris), Isolaz comes to aid of non-responders to traditional therapies -- whether topical, antibiotic or another laser -- and patients who had come to rely on Accutane, Aesthera Corporation suggests July 15. Drug maker Roche announced in June it was discontinuing distribution of Accutane (isotretinoin) due to increasing generic competition and the cost of product liability litigation, which have eaten into profits from what once was one of the company's top-selling products (1"The Pink Sheet" Daily, June 26, 2009). The move surprised some dermatologists and created concern that existing demand for isotretinoin could not be met, while Roche assured stakeholders that competing drug manufacturers would be able to supply the market. Regardless, "the bottom line is that physicians and patients need a viable alternative in their battle against acne," according to Aesthera CEO and President Alon Maor. In clinical testing Isolaz awarded immediate results within 24 to 48 hours and an 88% reduction in acne after four treatments without any of the side effects of systemic alternatives, the Pleasanton, Calif. firm says

You may also be interested in...



Roche Removes a Blemish: Drugmaker Drops Its One-Time Acne Blockbuster Accutane

Holding less than 5 percent of isotretinoin market and burdened with the costs of personal injury suits, Roche decides to discontinue its acne drug.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016283

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel